Chinese biopharmaceutical firm Akeso announced on Wednesday that its immunotherapy drug had outperformed AstraZeneca’s Imfinzi in a head-to-head phase-three trial for biliary tract cancer.The result represents another breakthrough for Akeso’s ivonescimab – which has already been licensed by the US firm Summit Therapeutics in a multibillion-dollar deal – as China’s biopharma industry increasingly looks to compete on the global stage.The Chinese trial tested ivonescimab and chemotherapy against AstraZeneca’s Imfinzi (durvalumab) plus chemotherapy on a total of 682 patients with advanced biliary tract cancer – a particularly deadly form of cancer with a five-year survival rate of less than 5 per cent, according to a Nature study.
SRCSouth China Morning Post
LANGEN
LEANCenter-Right
WORDS106
ENT8
THU · 2026-08-27 · 02:07 GMTBRIEF NSR-2026-0827-106323
NSR-2026-0827-106323News Report·EN·Technology
China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial
Chinese biopharmaceutical company Akeso announced that its immunotherapy drug, ivonescimab, demonstrated superior performance compared to AstraZeneca's Imfinzi in a Phase 3 trial for advanced biliary tract cancer. The trial, conducted in China, involved 682 patients and compared ivonescimab plus chemotherapy against Imfinzi (durvalumab) plus chemotherapy.
Julie ZhangSouth China Morning PostFiled 2026-08-27 · 02:07 GMTLean · Center-RightRead · 1 min
South China Morning PostFIG 01
Reading time
1min
Word count
106words
Sources cited
1cited
Entities identified
8entities
Quality score
100%
§ 01
Briefing Summary
AI-generatedNEWSAR · AI
Chinese biopharmaceutical company Akeso announced that its immunotherapy drug, ivonescimab, demonstrated superior performance compared to AstraZeneca's Imfinzi in a Phase 3 trial for advanced biliary tract cancer. The trial, conducted in China, involved 682 patients and compared ivonescimab plus chemotherapy against Imfinzi (durvalumab) plus chemotherapy. This outcome is a significant development for Akeso's ivonescimab, which has already been licensed by US firm Summit Therapeutics in a substantial deal. The results highlight the growing ambition of China's biopharmaceutical industry to compete globally. Biliary tract cancer is a highly lethal form of cancer with a low five-year survival rate.
Confidence 0.85Sources 1Claims 4Entities 8
§ 02
Article analysis
Model · rule-basedFraming
Technology
Economic Impact
Tone
Measured
AI-assessed
CalmNeutralAlarmist
Factuality
0.80 / 1.00
Factual
LowHigh
Sources cited
1
Limited
FewMany
§ 03
Key claims
4 extracted01
Akeso's ivonescimab has been licensed by US firm Summit Therapeutics in a multibillion-dollar deal.
factual
Confidence
1.00
02
Biliary tract cancer has a five-year survival rate of less than 5 percent.
statisticNature study
Confidence
1.00
03
The trial involved 682 patients with advanced biliary tract cancer.
statistic
Confidence
1.00
04
Akeso's immunotherapy drug ivonescimab outperformed AstraZeneca's Imfinzi in a head-to-head phase-three trial for biliary tract cancer.
factualAkeso
Confidence
1.00
§ 04
Full report
1 min read · 106 words§ 05
Entities
8 identifiedKey playerOppositionContextPositiveNeutralNegative
Organizations3
Locations1
§ 06
Keywords & salience
10 termsbiliary tract cancer
1.00
cancer drug
1.00
immunotherapy drug
0.90
phase 3 trial
0.90
akeso
0.80
imfinzi
0.80
biopharmaceutical
0.70
chemotherapy
0.60
ivonescimab
0.60
biopharma industry
0.50
§ 07
Topic connections
Interactive graph No topic relationship data available yet. This graph will appear once topic relationships have been computed.